Cryptococcosis among hospitalised patients with COVID-19: A multicentre research network study

22Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.
Get full text

Abstract

It is unclear if there is an association between COVID-19 and cryptococcosis. Therefore, this study aimed to describe the clinical features, risk factors, and outcomes associated with cryptococcosis in hospitalised patients with COVID-19. The objectives of this study were to determine the incidence of and examine factors associated with cryptococcosis after a diagnosis of COVID-19. We used TriNetX to identify and sort patients 18 years and older hospitalised with COVID-19 into two cohorts based on the presence or absence of a diagnosis of cryptococcosis following diagnosis of COVID-19. Outcomes of interest included the incidence of cryptococcosis following the diagnosis of COVID-19 as well as the proportion of patients in each group who had underlying comorbidities, received immunomodulatory therapy, required ICU admission or mechanical ventilation (MV), or died. Propensity score matching was used to adjust for confounding. Among 212,479 hospitalised patients with COVID-19, 65 developed cryptococcosis. The incidence of cryptococcosis following COVID-19 was 0.022%. Patients with cryptococcosis were more likely to be male and have underlying comorbidities. Among cases, 32% were people with HIV. Patients with cryptococcosis were more likely to have received tocilizumab (p

Cite

CITATION STYLE

APA

Chastain, D. B., Kung, V. M., Golpayegany, S., Jackson, B. T., Franco-Paredes, C., Vargas Barahona, L., … Henao-Martínez, A. F. (2022). Cryptococcosis among hospitalised patients with COVID-19: A multicentre research network study. Mycoses, 65(8), 815–823. https://doi.org/10.1111/myc.13476

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free